

Press Release
Västra Frölunda, Sweden, January 19, 2012

Artimplant takes over sales in the Nordic countries

Artimplant continues to strengthen its market position. Since the beginning of 2012, Artimplant has taken over the sales of their products on the Nordic market.

The former distributor, NMS, has filed for bankruptcy, enabling Artimplant to quickly take over the direct sales. This is a part of Artimplant's effort to increase its presence in markets where Artimplant's products are marketed and distributed.

Västra Frölunda, January 19, 2012
Kjell Thörnbring

For further information, please contact:

Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone: +46 703 11 90 25

Further information at www.artimplant.com where one also can subscribe to future press releases;
www.artimplant.com/investors-media/subscribe-to-press-releases.html

Artimplant

Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon[®], meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on January 19, 2012 at 09:00 AM (Swedish time).